Document is current

Article History

Accepted: 25 March 2021

First Online: 12 May 2021

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Not relevant.

: A.M. declares research funding from the UK Medical Research Council (MR/S005714/1). C.B. is employed by the University of Glasgow which holds consultancy and/or research agreements with companies that have commercial interests in the diagnosis and treatment of ischemic heart disease. The companies include Abbott Vascular, AstraZeneca, Boehringer Ingelheim, GSK, HeartFlow, Menarini Farmaceutica, Opsens, Philips and Siemens Healthcare.MM declares – CJP declares research funding from NHLBI grant nos. R01 HL 132448, R01 HL091005, U01 HL064924, U01 HL087366, UM1 HL087366; UM1 HL087366, UM1 HL087364; NIH/National Center for Advancing Translational Sciences UL1 TR001427; US Department of Defencse grant nos. W81XWH1720030, ; NIH/Brigham and Women’s Hospital 5U01 HL130163-02; GE Healthcare GE-265-303; ; University of Florida Office of Research AGR DTD 04-26-2018; CSL Behring, LLC. CSL112-3001; BioCardia BC-14-001-02; Mesoblast, Inc. MSB-MPC-CHF001; Ventrix, Inc.; Athersys Inc. AMI MultiStem; Verily Life Sciences LLC-Project Baseline OSMB; Ironwood MSB-MPC-CHF00-DMC, Imbria Pharmaceuticals Inc.; Milestone Pharmaceuticals Inc.; Caladrius Biosciences, Inc.; and the Gatorade Trust.